Skip to main content

Table 4 Clinical outcomes by treatment group

From: The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients

  PMX-HP group Non PMX-HP group P valuea
Overall n = 29 n = 30  
 Mortality on day 3, n (%) 3 (10.3) 10 (33.3) 0.058
 Mortality on day 7, n (%) 6 (20.7) 12 (40.0) 0.11
 Mortality on day 28, n (%) 17 (58.6) 15 (50.0) 0.51
 MAKE 28b (%) 22 (75.9) 22 (73.3) 1.00
Alive on day 28 n=13c n = 15  
 ICU-free days (Q1, Q3) 0 (0, 10) 0 (0, 8) 0.99
 Ventilator-free days (Q1, Q3) 0 (0, 8) 0 (0, 0) 0.28
 RRT, n (%) 7 (53.8) 6d (50.0) 0.85
 Serum creatinine (mg/dl) (Q1, Q3) 1.4 (1.1, 2.2) 2.1 (1.3, 2.5) 0.59
 Vasopressor free days (Q1, Q3) 0 (0, 25) 11.5 (0, 25) 0.47
AKI at baseline n = 25 n = 25  
 Renal recoverye, n (%) 5 (20.0) 3 (12.0) 0.70
  1. Data represent median (25th percentile, 75th percentile) unless otherwise noted
  2. Data measured on day 28 unless otherwise noted
  3. PMX-HP polymyxin B hemoperfusion, ICU intensive care unit, Q1 25th percentile, Q3 75th percentile, RRT renal replacement therapy, AKI acute kidney injury
  4. aFisher’s exact test for categorical variables; Kruskal–Wallis test for continuous variables
  5. bMajor adverse kidney events on day 28, comprised of death, or dialysis dependence, or persistent AKI on day 28
  6. cIn the PMX-HP group one patient died by the end of day 28, but his values were measured and used in the analysis
  7. dIn the non-PMX-HP group, RRT data were available in 12 patients
  8. eRenal recovery mean alive, dialysis independence and no AKI on day 28 after enrollment